Target intelligence / Profile preview

Bloom syndrome protein (BLM)

Target
BLM
Molecular classification
Enzyme (ATP-dependent DNA helicase), RecQ DNA helicase family, Genome stability protein
01

Overview

Bloom syndrome protein (BLM) is a highly conserved ATP-dependent DNA helicase of the RecQ family. It unwinds double-stranded DNA in the 3'-5' direction and is essential for the maintenance of genome integrity. BLM plays a critical role in DNA replication, recombination, and repair, particularly at sites of complex DNA structures such as Holliday junctions. The protein suppresses excess sister chromatid exchanges and unwinds alternative DNA structures—including triple helix and G-quadruplex arrangements—that arise during replication and repair. Mutations in the BLM gene cause Bloom syndrome, a rare inherited disorder defined by high rates of genomic instability, cancer predisposition, immunodeficiency, and premature aging. BLM interacts physically with proteins such as replication protein A (RPA), topoisomerase IIIα, BRCA1, Rad51, and others, coordinating critical aspects of DNA metabolism. Dysregulation or mutation of BLM is directly associated with increased risks for various cancers and is under investigation as a synthetic lethality target for DNA-damaging therapeutics

Other names
Bloom syndrome proteinDNA helicase BLMRecQ-like DNA helicase BLMRecQ protein-like 3RECQ2RECQL3BSMGRISCE1DNA 3'-5' helicase BLM
02

Mechanism of action

Drugs causing DNA damage or inhibiting DNA repair may exploit BLM deficiency for synthetic lethality (conceptual approach is similar to PARP inhibitors in BRCA-deficient cancer)

03

Biological functions

DNA replicationDNA repairDNA recombinationMaintenance of genomic stabilitySuppression of excessive sister chromatid exchangesResolution of DNA structures such as Holliday junctions, triple helices, and G-quadruplexes
04

Disease associations

Cancer (tumor suppressor and possible pro-oncogenic functions depending on cellular context)Bloom syndrome (autosomal recessive disorder characterized by genomic instability and cancer predisposition)Premature agingImmunodeficiencyPulmonary diseases
05

Safety considerations

Destabilization of genomic integrity in BLM-deficient cells increases risk for mutagenesis, cancer predisposition, and cell deathPossible off-target effects in therapeutic strategies—genome instability and cytotoxicity
06

Interacting drugs

Chemotherapeutic agents
07

Biomarkers

Increased sister chromatid exchange rate (diagnostic for Bloom syndrome)BLM expression/mutation status for cancer risk stratification/therapeutic sensitivity

Beyond the preview

Go deeper on Bloom syndrome protein (BLM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bloom syndrome protein (BLM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call